Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of ISIS 703802 in Healthy Volunteers with Elevated Triglycerides and Familial Hypercholesterolemia
NCT02709850Phase 1Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Nov 2015
- Primary completion
- Apr 2017
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vupanorsen in hypertriglyceridemia and familial hypercholesterolemia (FH) (11 arms), sponsored by Ionis Pharmaceuticals. Primary endpoints: Safety and tolerability of single and multiple doses of IONIS ANGPTL3-LRx, Pharmacokinetics of IONIS ANGPTL3-LRx and 1 more. Started Nov 2015; status: completed.
02
Drugs
vupanorsen
03
Conditions
hypertriglyceridemiafamilial hypercholesterolemia (FH)
Beyond the preview
Go deeper on NCT02709850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02709850.